Gilead faces fights over hepatitis C and HIV drugs

Maura Healey, the attorney general of Massachusetts, has opened an inquiry into whether Gilead Sciences had violated state consumer protection laws by charging too much for its hepatitis C virus (HCV) drugs. Her action comes on the heels of a lawsuit filed Tuesday by the AIDS Healthcare Foundation, seeking to invalidate patents covering the new version of Gilead’s mainstay HIV drug, tenofovir.